PABPC1L

Across TCGA pan-cancer cohorts, PABPC1L mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PABPC1L data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PABPC1L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PABPC1L expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where PABPC1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.443	1.000	.005	19	view →
PDAC	OS	Median	II,III,IV	0.264	0.527	.004	11	view →
LSCC	OS	Quartile	All	1.000	0.392	.020	8	view →
LUAD	DFS	Quartile	II,III,IV	0.890	0.410	.018	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PABPC1L–CCRCC (DFS)

Open the CCRCC breakdown →